GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

OTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (OTCQB:GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research...

from PR Newswire: https://prn.to/2MdYA6j